Avet Loiseau H et al. Daratumumab (DARA) with bortezomib, thalidomide, and dexamethasone (VTd) in transplant-eligible patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) negativity in Cassiopeia part 1 and part 2. ASH 2021;Abstract 82.
Chari A et al. Phase 1b results for subcutaneous talquetamab plus daratumumab in patients with relapsed/refractory multiple myeloma. ASH 2021;Abstract 161.
Cohen YC et al. Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR) T-cell therapy, in lenalidomide-refractory patients with progressive multiple myeloma after 1-3 prior lines of therapy: Updated results from CARTITUDE-2. ASH 2021;Abstract 3866.
Costa LJ et al. Daratumumab, carfilzomib, lenalidomide and dexamethasone (dara-krd), autologous transplantation and MRD response-adapted consolidation and treatment cessation. Final primary endpoint analysis of the Master trial. ASH 2021;Abstract 481.
Fonseca R et al. First-line use of daratumumab, lenalidomide, and dexamethasone confers survival benefit compared with second-line use of daratumumab-based regimens in transplant-ineligible patients with multiple myeloma: Analysis of different clinical scenarios. ASH 2021;Abstract 118.
Goldschmidt H et al. Addition of isatuximab to lenalidomide, bortezomib and dexamethasone as induction therapy for newly-diagnosed, transplant-eligible multiple myeloma patients: The phase III GMMG-HD7 trial. ASH 2021;Abstract 463.
Krishnan AY et al. Updated phase 1 results from MonumenTAL-1: First-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma. ASH 2021;Abstract 158.
Kumar SK et al. Final overall survival results from BELLINI, a phase 3 study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. ASH 2021;Abstract 84.
Laubach JP et al. Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients (pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): Updated analysis of GRIFFIN after 24 months of maintenance. ASH 2021;Abstract 79.
Martin T et al. Updated results from CARTITUDE-1: Phase 1b/2study of ciltacabtagene autoleucel, a B-cell maturation antigen–directed chimeric antigen receptor T cell therapy, in patients with relapsed/refractory multiple myeloma. ASH 2021;Abstract 549.
Mateos M-V et al. Ciltacabtagene autoleucel for triple-class exposed multiple myeloma: Adjusted comparisons of CARTITUDE-1 patient outcomes versus therapies from real-world clinical practice from the LocoMMotion prospective study. ASH 2021;Abstract 550.
Moreau P et al. Updated results from MajesTEC-1: Phase 1/2 study of teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in relapsed/refractory multiple myeloma. ASH 2021;Abstract 896.
Sebag M et al. Elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients with relapsed or refractory multiple myeloma: Results from Magnetismm-1. ASH 2021;Abstract 895.
Sudalagunta PR et al. Rationale for selinexor treatment in daratumumab-refractory multiple myeloma patients identified by paired ex vivo drug sensitivity and RNA-seq. ASH 2021;Abstract 893.
Trudel S et al. Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed/refractory multiple myeloma (RRMM): Updated results from an ongoing phase I study. ASH 2021;Abstract 157.